IFN-γ and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease

Journal of Immunology

Volumn 179, Issue 3, 2007, Pages 1669-1680

  Ramirez Montagut, Teresa ^a,b   Chow, Andrew ^a   Kochman, Adam A ^a   Smith, Odette M ^a   Suh, David ^a   Sindhi, Hamad ^a   Lu, Sydney ^a   Borsotti, Chiara ^a   Grubin, Jeremy ^a   Patel, Neel ^a   Terwey, Theis H ^a   Kim, Theo D ^a   Heller, Glenn ^a   Murphy, George F ^c   Liu, Chen ^d   Alpdogan, Onder ^a   Van Den Brink, Marcel R M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; FAS ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; KIDNEY ALLOGRAFT; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL MOTION; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MORTALITY; MOUSE; MOUSE MUTANT; PHYSIOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD95; BONE MARROW TRANSPLANTATION; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 34548605451     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.3.1669     Document Type: Article

References (52)

1. Ferrara, J. L., R. Levy, and N. J. Chao. 1999. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol. Blood Marrow Transplant. 5: 347-356.
2. van den Brink, M. R., and S. J. Burakoff. 2002. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat. Rev. Immunol. 2: 273-281.
3. Lee, S., S. Y. Chong, J. W. Lee, S. C. Kim, Y. H. Min, J. S. Hahn, and Y. W. Ko. 1997. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD. Bone Marrow Transplant. 20: 883-888.
4. + T cell activation and IFN-γ production. J. Immunol. 161: 2848-2855.
5. Wasem, C., C. Frutschi, D. Arnold, C. Vallan, T. Lin, D. R. Green, C. Mueller, and T. Brunner. 2001. Accumulation and activation-induced release of preformed Fas (CD95) ligand during the pathogenesis of experimental graft-versus-host disease. J. Immunol. 167: 2936-2941.
6. Hattori, K., T. Hirano, H. Miyajima, N. Yamakawa, M. Tateno, K. Oshimi, N. Kayagaki, H. Yagita, and K. Okumura. 1998. Differential effects of anti-Fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host disease pathologies. Blood 91: 4051-4055.
7. Piguet, P. F., G. E. Grau, B. Allet, and P. Vassalli. 1987. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166: 1280-1289.
8. Herve, P., M. Flesch, P. Tiberghien, J. Wijdenes, E. Racadot, P. Bordigoni, E. Plouvier, J. L. Stephan, H. Bourdeau, E. Holler, et al. 1992. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79: 3362-3368.
9. Teshima, T., G. R. Hill, L. Pan, Y. S. Brinson, M. R. van den Brink, K. R. Cooke, and J. L. Ferrara. 1999. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J. Clin. Invest. 104: 317-325.
10. Schmaltz, C., O. Alpdogan, K. J. Horndasch, S. J. Muriglan, B. J. Kappel, T. Teshima, J. L. Ferrara, S. J. Burakoff, and M. R. van den Brink. 2001. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97: 2886-2895.
11. Tsukada, N., T. Kobata, Y. Aizawa, H. Yagita, and K. Okumura. 1999. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93: 2738-2747.
12. Pan, L., T. Teshima, G. R. Hill, D. Bungard, Y. S. Brinson, V. S. Reddy, K. R. Cooke, and J. L. Ferrara. 1999. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood 93: 4071-4078.
13. Hsieh, M. H., and R. Korngold. 2000. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 96: 1047-1055.
14. Schmaltz, C., O. Alpdogan, B. J. Kappel, S. J. Muriglan, J. A. Rotolo, J. Ongchin, L. M. Willis, A. S. Greenberg, J. M. Eng, J. M. Crawford, et al. 2002. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8: 1433-1437.
15. Ito, M., and J. A. Shizuru. 1999. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biol. Blood Marrow Transplant. 5: 357-368.
16. Espinoza-Delgado, I., and R. W. Childs. 2004. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy. Expert Rev. Anticancer Ther. 4: 865-875.
17. Srinivasan, R., J. Barrett, and R. Childs. 2004. Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. Semin. Oncol. 31: 47-55.
18. Childs, R., A. Chernoff, N. Contentin, E. Bahceci, D. Schrump, S. Leitman, E. J. Read, J. Tisdale, C. Dunbar, W. M. Linehan, et al. 2000. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343: 750-758.
19. Lundqvist, A., and R. Childs. 2005. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J. Immunother. 28: 281-288.
20. Ponomarev, V., M. Doubrovin, I. Serganova, J. Vider, A. Shavrin, T. Beresten, A. Ivanova, L. Ageyeva, V. Tourkova, J. Balatoni, et al. 2004. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur. J. Nucl. Med. Mol. Imaging 31: 740-751.
21. Cooke, K. R., L. Kobzik, T. R. Martin, J. Brewer, J. Delmonte, Jr., J. M. Crawford, and J. L. Ferrara. 1996. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood 88: 3230-3239.
22. Hill, G. R., J. M. Crawford, K. R. Cooke, Y. S. Brinson, L. Pan, and J. L. Ferrara. 1997. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90: 3204-3213.
23. Ferrara, J., F. J. Guillen, B. Sleckman, S. J. Burakoff, and G. F. Murphy. 1986. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J. Invest. Dermatol. 86: 371-375.
24. Vardi, Y., Z. L. Ying, and C. H. Zhang. 2001. Two-sample tests for growth curves under dependent right censoring. Biometrika 88: 949-960.
25. Lyons, S. K. 2005. Advances in imaging mouse tumour models in vivo. J. Pathol. 205: 194-205.
26. Seki, N., A. D. Brooks, C. R. Carter, T. C. Back, E. M. Parsoneault, M. J. Smyth, R. H. Wiltrout, and T. J. Sayers. 2002. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168: 3484-3492.
27. Sayers, T. J., A. D. Brooks, N. Seki, M. J. Smyth, H. Yagita, B. R. Blazar, and A. M. Malyguine. 2000. T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas. J. Leukocyte Biol. 68: 81-86.
28. Seki, N., Y. Hayakawa, A. D. Brooks, J. Wine, R. H. Wiltrout, H. Yagita, J. E. Tanner, M. J. Smyth, and T. J. Sayers. 2003. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 63: 207-213.
29. Ruuls, S. R., R. M. Hoek, V. N. Ngo, T. McNeil, L. A. Lucian, M. J. Janatpour, H. Korner, H. Scheerens, E. M. Hessel, J. G. Cyster, et al. 2001. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15: 533-543.
30. Yang, Y. G., J. Qi, M. G. Wang, and M. Sykes. 2002. Donor-derived interferon γ separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 99: 4207-4215.
31. Yang, Y. G., B. R. Dey, J. J. Sergio, D. A. Pearson, and M. Sykes. 1998. Donor-derived interferon γ is required for inhibition of acute graft-versus-host disease by interleukin 12. J. Clin. Invest. 102: 2126-2135.
32. Murphy, W. J., L. A. Welniak, D. D. Taub, R. H. Wiltrout, P. A. Taylor, D. A. Vallera, M. Kopf, H. Young, D. L. Longo, and B. R. Blazar. 1998. Differential effects of the absence of interferon-γ and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J. Clin. Invest. 102: 1742-1748.
33. Reddy, P., T. Teshima, M. Kukuruga, R. Ordemann, C. Liu, K. Lowler, and J. L. Ferrara. 2001. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194: 1433-1440.
34. Brok, H. P., P. J. Heidt, P. H. van der Meide, C. Zurcher, and J. M. Vossen. 1993. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J. Immunol. 151: 6451-6459.
35. Yang, Y. G., J. J. Sergio, D. A. Pearson, G. L. Szot, A. Shimizu, and M. Sykes. 1997. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood 90: 4651-4660.
36. Ellison, C. A., D. S. Bradley, J. M. Fischer, K. T. Hayglass, and J. G. Gartner. 2002. Murine graft-versus-host disease induced using interferon-γ-deficient grafts features antibodies to double-stranded DNA, T helper 2-type cytokines and hypereosinophilia. Immunology 105: 63-72.
37. Welniak, L. A., B. R. Blazar, M. R. Anver, R. H. Wiltrout, and W. J. Murphy. 2000. Opposing roles of interferon-β on CD4 T cell-mediated graft-versus-host disease: effects of conditioning. Biol. Blood Marrow Transplant. 6: 604-612.
38. Bukowski, R. M., P. Rayman, L. Molto, C. S. Tannenbaum, T. Olencki, D. Peereboom, R. Tubbs, D. McLain, G. T. Budd, T. Griffin, et al. 1999. Interferon-γ and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin. Cancer Res. 5: 2780-2789.
39. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and T. A. Hamilton. 1998. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161: 927-932.
40. Sgadari, C., J. M. Farber, A. L. Angiolillo, F. Liao, J. Teruya-Feldstein, P. R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato. 1997. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 89: 2635-2643.
41. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182: 155-162.
42. Luster, A. D., S. M. Greenberg, and P. Leder. 1995. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182: 219-231.
43. Sayers, T. J., A. D. Brooks, J. K. Lee, R. G. Fenton, K. L. Komschlies, J. M. Wigginton, R. Winkler-Pickett, and R. H. Wiltrout. 1998. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J. Immunol. 161: 3957-3965.
44. Takeda, K., M. J. Smyth, E. Cretney, Y. Hayakawa, N. Yamaguchi, H. Yagita, and K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-γ-dependent suppression of subcutaneous tumor growth. Cell. Immunol. 214: 194-200.
45. Smyth, M. J., E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193: 661-670.
46. Hill, G. R., W. Krenger, and J. L. Ferrara. 1997. The role of cytokines in acute graft-versus-host disease. Cytokines Cell. Mol. Ther. 3: 257-266.
47. Krenger, W., K. R. Cooke, J. M. Crawford, S. T. Sonis, R. Simmons, L. Pan, J. Delmonte, Jr., M. Karandikar, and J. L. Ferrara. 1996. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 62: 1278-1285.
48. Ferrara, J. L., and W. Krenger. 1998. Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. Transfus. Med. Rev. 12: 1-17.
49. Zoller, M. 2003. Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host. J. Immunol. 171: 6941-6953.
50. Harano, M., M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito. 2005. Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice. Cancer Res. 65: 10032-10040.
51. + IFN-γ-producing T cells. Bone Marrow Transplant. 33: 491-497.
52. Tykodi, S. S., E. H. Warren, J. A. Thompson, S. R. Riddell, R. W. Childs, B. E. Otterud, M. F. Leppert, R. Storb, and B. M. Sandmaier. 2004. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 10: 7799-7811.